Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development
\nRoots Analysis has announced the addition of \u201cGene Therapy Market, 2022-2035\u201d report to its list of offerings.
\nPost the emergence of blockbuster gene therapies, such as ZOLGENSMA\u00ae (for spinal muscular atrophy type I) and Libmeldy\u2122 (for metachromatic leukodystrophy), this domain has garnered significant interest in the medical community. Moreover, considering the promising trial results of pipeline candidates, notable players have made investments to support product development and commercialization efforts.
\nGet Detailed Report: https:\/\/www.rootsanalysis.com\/reports\/view_document\/gene-therapies-market\/268.html
\nKey Market Insights
\nOver 1,150 gene therapies are currently being developed across different stages
\nApart from 11 approved products, most of the aforementioned therapies (70%) are in early stages of development (preclinical \/ discovery), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of the clinical stage candidates target oncological diseases. Further, majority of such therapies (66%) use adenovirus vectors as molecular carriers.
\nMore than 250 companies claim to be engaged in the development of gene therapies, globally
\nIn the past decade, over 160 companies have been established in this domain. Of the total, 60% of the players are small firms. In addition, majority (62%) of these gene therapy developers are based in North America, primarily in the US.
\n290+ clinical trials evaluating gene therapies have been registered, worldwide
\nOf the total number of trials registered during the period 2015-2020, close to 10% have already been completed, while 56% are presently recruiting patients. Further, presently, around 55% of the trials are evaluating therapy candidates in phase II studies.
\nUSD 8.5+ billion has been invested by both private and public investors, since 2015
\nThe maximum funding amount was raised through secondary offerings (40%), venture capital (28%) and IPOs (16%), during the period 2015-2022. Interestingly, majority (77%) of the funding instances were reported by players based in North America.
\nRequest for Customization @ Gene Therapy Market is projected to grow at CAGR of 18% by 2035
\nOver 5,800 patents have been filed \/ published related to gene therapies, since 2017
\nAround 90% of the total number of patent applications were related to gene therapies, while the remaining were focused on gene editing-based therapies. Further, majority of the patent assignees were industry players. However, it is worth mentioning that the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 19%), over the past few years.
\nMerger and acquisition activity in this market has grown at a CAGR of 22%, during 2015-2021
\nIt is worth mentioning that, across most of the instances (43%) both the acquirer and the acquired company were based in North America. Moreover, majority of the acquisitions (26%) were focused on providing access to novel platform \/ technology, followed by acquisitions undertaken for therapeutic area consolidation (24%) and drug class consolidation (24%).
\nThe overall market is anticipated to grow at a CAGR of over 18%, during the period 2022-2035
\nGene therapies based on gene augmentation currently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. North America (primarily the US) is expected to capture 60% of the market share by 2035, in terms of the sales-based revenues.
\nKey Questions Answered
\n\u2022 Who are the key industry players engaged in the development of gene therapies?
\n\u2022 How many gene therapy candidates are currently in the development pipeline? Which key disease indications are targeted by such products?
\n\u2022 Which types of vectors are most commonly used for effective delivery of gene therapies?
\n\u2022 What are the key regulatory requirements for gene therapy approval, across various geographies?
\n\u2022 Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of the development cycle?
\n\u2022 What are the different pricing models and reimbursement strategies currently being adopted for gene therapies?
\n\u2022 What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?
\n\u2022 Who are the key CMOs \/ CDMOs engaged in supplying viral \/ plasmid vectors for gene therapy development?
\n\u2022 What are the key value drivers of the merger and acquisition activity in the gene therapy industry?
\n\u2022 Who are the key stakeholders that have actively made investments in the gene therapy domain?
\n\u2022 Which are the most active trial sites (in terms of number of clinical studies being conducted) for gene therapies?<\/p>\n
Gene Therapy Market is projected to grow at CAGR of 18% by 2035?<\/p>\n
\u2022 How is the current and future market opportunity likely to be distributed across key market segments?
\nRequest for Sample: https:\/\/www.rootsanalysis.com\/reports\/268\/request-sample.html
\nThe financial opportunity within the gene therapy market has been analyzed across the following segments:
\nType of Therapy
\n\u2022 Gene augmentation
\n\u2022 Immunotherapy
\n\u2022 Oncolytic viral therapy
\n\u2022 Others
\nType of Gene Delivery Method Used
\n\u2022 Ex vivo
\n\u2022 In vivo
\nType of Vector Used
\n\u2022 Adeno-associated virus
\n\u2022 Adenovirus
\n\u2022 Herpes simplex virus
\n\u2022 Lentivirus
\n\u2022 Non-viral vectors
\n\u2022 Retrovirus
\n\u2022 Others
\nTarget Therapeutic Areas
\n\u2022 Cardiovascular diseases
\n\u2022 Dermatological diseases
\n\u2022 Genetic diseases
\n\u2022 Hematological diseases
\n\u2022 Infectious diseases
\n\u2022 Metabolic diseases
\n\u2022 Muscle-related diseases
\n\u2022 Oncological diseases
\n\u2022 Ophthalmic diseases
\n\u2022 Others
\nRoute of Administration
\n\u2022 Intraarticular
\n\u2022 Intracerebral
\n\u2022 Intracoronary
\n\u2022 Intradermal
\n\u2022 Intralesional
\n\u2022 Intramuscular
\n\u2022 Intrapleural
\n\u2022 Intrathecal
\n\u2022 Intratumoral
\n\u2022 Intravenous
\n\u2022 Intravesical
\n\u2022 Intravitreal
\n\u2022 Subretinal
\n\u2022 Topical
\n\u2022 Others
\nKey Geographical Regions
\n\u2022 North America
\n\u2022 Europe
\n\u2022 Asia-Pacific
\n\u2022 Rest of the World
\nThe research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration and recent developments (if available).
\n\u2022 Abeona Therapeutics
\n\u2022 AGTC
\n\u2022 AnGes
\n\u2022 Biogen
\n\u2022 BioMarin Pharmaceutical
\n\u2022 bluebird bio
\n\u2022 Castle Creek Biosciences
\n\u2022 CG Oncology
\n\u2022 FerGene
\n\u2022 GenSight Biologics
\n\u2022 Helixmith
\n\u2022 Holostem Terapie Avanzate
\n\u2022 Inovio Pharmaceuticals
\n\u2022 Kolon TissueGene
\n\u2022 Krystal Biotech
\n\u2022 Lysogene
\n\u2022 Neurophth Therapeutics
\n\u2022 Orchard Therapeutics
\n\u2022 Pfizer
\n\u2022 PTC Therapeutics
\n\u2022 REGENXBIO
\n\u2022 Sangamo Therapeutics
\n\u2022 Spark Therapeutics
\n\u2022 VBL Therapeutics
\nInquiry before Purchasing: https:\/\/www.rootsanalysis.com\/reports\/268\/ask-question.html<\/p>\n
Read Our Latest Press Release:
\n6. https:\/\/www.rootsanalysis.com\/press-releases\/clinical-trial-planning-and-design-services-market.html
\n7. https:\/\/www.rootsanalysis.com\/press-releases\/large-volume-wearable-injectors-market.html
\n8. https:\/\/www.rootsanalysis.com\/press-releases\/teleradiology-services-market.html
\n9. https:\/\/www.rootsanalysis.com\/press-releases\/porphyria-targeting-therapies-market.html
\n10. https:\/\/www.rootsanalysis.com\/press-releases\/squamous-non-small-cell-lung-cancer-market.html
\nVisit for More Insights: https:\/\/www.rootsanalysis.com\/reports.html
\nRead Our Latest Press Release: https:\/\/www.rootsanalysis.com\/press-releases.html
\nLatest Blogs On Healthcare Industry: https:\/\/www.rootsanalysis.com\/blog\/<\/p>\n
Gene Therapy Market is projected to grow at CAGR of 18% by 2035<\/p>\n
Given the potential of gene therapies to permanently cure a diverse array of clinical conditions…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[40,44],"tags":[731,730,726,729,727,728,725],"yoast_head":"\n